Efficacy and safety of regorafenib for the treatment of metastatic colorectal cancer in routine clinical practice: results from a Spanish hospital.

Introduction: Regorafenib is indicated as treatment in third-line and beyond in patients with metastatic colorectal cancer.

Methods: This is a retrospective study of a cohort of patients with mCRC treated with regorafenib in Hospital Universitario Ramón y Cajal, in Madrid, Spain.

Results: With the aim to assess the efficacy and safety of regorafenib, 91 patients treated between 2013 and 2023 were included.